Esophagus Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ESP025 MIFTS: 63	Esophagus Adenocarcinoma Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Esophagus Adenocarcinoma

MalaCards integrated aliases for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma ¹¹ ¹⁴

Esophageal Adenocarcinoma ⁵⁸ ¹⁶ ⁷⁵

Adenocarcinoma of Esophagus ⁴³ ⁷¹

Oesophageal Adenocarcinoma ¹¹ ³³

Adenocarcinoma of the Esophagus ⁵⁸

Characteristics:

Prevelance:

Adenocarcinoma of the Esophagus: 1-9/100000 (Europe, Europe, Europe, Austria, Belgium, Czech Republic, Finland, France, Germany, Iceland, Ireland, Malta, Switzerland, Netherlands, United Kingdom, Norway, Spain) 1-9/1000000 (Worldwide, Bulgaria, Croatia, Estonia, Italy, Latvia, Lithuania, Poland, Portugal, Slovakia, Slovenia) ⁵⁸

Age Of Onset:

Adenocarcinoma of the Esophagus: Adult,Elderly ⁵⁸

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Gastrointestinal diseases Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of oesophagus

Malignant neoplasm: Abdominal part of oesophagus

Malignant neoplasm: Lower third of oesophagus

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of digestive organs

Malignant neoplasms of oesophagus

Adenocarcinoma of oesophagus

Adenocarcinoma of oesophagus, unspecified

Other specified adenocarcinoma of oesophagus

Orphanet: ⁵⁸

Rare gastroenterological diseases

External Ids:

Disease Ontology ¹¹ DOID:4914

MeSH ⁴³ C562730

NCIt ⁴⁹ C4025

SNOMED-CT ⁶⁸ 276803003

ICD10 via Orphanet ³² C15.2 C15.5

UMLS via Orphanet ⁷² C0279628

Orphanet ⁵⁸ ORPHA99976

SNOMED-CT via HPO ⁶⁹ 16331000 16932000 235595009 more

EFO ¹⁶ EFO_0000478

ICD11 ³³ 829915640 829915640/other 829915640/unspecified

UMLS ⁷¹ C0279628

Sources

Summaries for Esophagus Adenocarcinoma

Orphanet: ⁵⁸ Esophageal adenocarcinoma (EAC) is a sub-type of esophageal carcinoma (EC; see this term) affecting the glandular cells of the lower esophagus at the junction with the stomach.

MalaCards based summary: Esophagus Adenocarcinoma, also known as esophageal adenocarcinoma, is related to peptic esophagitis and adenocarcinoma. An important gene associated with Esophagus Adenocarcinoma is HNF1A-AS1 (HNF1A Antisense RNA 1), and among its related pathways/superpathways are Cell differentiation - expanded index and Head and neck squamous cell carcinoma. The drugs FOLFIRINOX and Pertuzumab have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and bone marrow, and related phenotypes are gastroesophageal reflux and feeding difficulties in infancy

Disease Ontology: ¹¹ An esophageal carcinoma that derives from epithelial cells of glandular origin.

Wikipedia: ⁷⁵ Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and... more...

Sources

Related Diseases for Esophagus Adenocarcinoma

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 644)

#	Related Disease	Score	Top Affiliating Genes
1	peptic esophagitis	30.9	CDX2 ATP4A ATP12A
2	adenocarcinoma	30.7	TP53 HNF1A-AS1 ERBB2 EGFR CDX2
3	gastroesophageal junction adenocarcinoma	30.7	TP53 ERBB2 EGFR
4	appendix adenocarcinoma	30.6	TP53 CDX2
5	cardia cancer	30.5	TP53 ERBB2 ATP4A ATP12A
6	atrophic gastritis	30.5	MIR196A1 CDX2 ATP4A ATP12A
7	mucinous adenocarcinoma	30.5	TP53 ERBB2 EGFR CDX2
8	pylorospasm	30.5	ATP4A ATP12A
9	barrett's adenocarcinoma	30.4	TP53 ERBB2 CDX2 ATP4A ATP12A
10	bile reflux	30.4	CDX2 ATP4A ATP12A
11	gastritis	30.4	TP53 MIR196A1 CDX2 ATP4A
12	alcohol use disorder	30.3	MIR199A1 MIR196A1 ATP12A
13	squamous cell carcinoma	30.2	TP53 MIR199A1 HNF1A-AS1 ERBB2 EGFR
14	achalasia	30.2	TP53 ATP4A ATP12A
15	barrett esophagus	30.2	TP53 TFF3 MIR196A1 ERBB2 CDX2 ATP4A
16	gastroesophageal adenocarcinoma	30.1	TP53 ERBB2 EGFR
17	signet ring cell adenocarcinoma	30.1	TP53 ERBB2 CDX2
18	exanthem	30.1	ERBB2 EGFR ATP12A
19	adenocarcinoma in situ	30.1	TP53 EGFR CDX2
20	small cell cancer of the lung	30.1	TP53 MIR21 EGFR
21	intestinal obstruction	30.1	CDX2 ATP4A ATP12A
22	apocrine adenocarcinoma	30.1	TP53 ERBB2 EGFR
23	tongue carcinoma	30.1	TP53 MIR21 MIR143 EGFR
24	glioma susceptibility 1	30.0	TP53 MIR21 ERBB2
25	skin carcinoma	30.0	TP53 MIR21 MIR199A1 ERBB2 EGFR
26	papillary adenocarcinoma	30.0	TP53 MIR21 ERBB2 CDX2
27	diffuse large b-cell lymphoma	30.0	MIR21 MIR199A1 MIR196A1 MIR145 MIR143
28	large cell carcinoma	29.9	TP53 MIR145 ERBB2 EGFR
29	kidney cancer	29.9	TP53 MIR21 MIR199A1 MIR193A MIR145 EGFR
30	intrahepatic cholangiocarcinoma	29.9	TP53 MIR199A1 ERBB2 EGFR
31	neurofibroma	29.9	TP53 ERBB2 EGFR
32	rectal benign neoplasm	29.9	TP53 MIR145 MIR143 LEPROTL1 EGFR CDX2
33	cholangiocarcinoma	29.9	TP53 MIR21 ERBB2 EGFR CDX2 AFAP1-AS1
34	lynch syndrome	29.9	TP53 ERBB2 EGFR CDX2
35	rectum cancer	29.9	TP53 MIR215 MIR21 MIR193A MIR145 MIR143
36	colorectal adenocarcinoma	29.8	TP53 MIR193A MIR145 MIR143 ERBB2 EGFR
37	gastroesophageal reflux	29.8	TP53 EGFR CDX2 ATP4A ATP12A
38	hematologic cancer	29.8	MIR21 MIR199A1 MIR196A1 MIR193A MIR145 MIR143
39	microinvasive gastric cancer	29.8	TP53 MIR199A1 MIR196A1 ERBB2 CDX2 ATP4A
40	bladder cancer	29.7	TP53 MIR21 MIR199A1 MIR145 MIR143 HNF1A-AS1
41	esophageal disease	29.7	TP53 MIR330 MIR21 MIR199A1 MIR196A1 MIR193A
42	lymphatic system disease	29.7	TP53 MIR21 MIR199A1 MIR196A1 MIR193A MIR145
43	oropharynx cancer	29.7	TP53 MIR21 MIR199A1 MIR196A1 ERBB2 EGFR
44	lung squamous cell carcinoma	29.7	TP53 MIR330 MIR196A1 MIR193A MIR145 EGFR
45	gastrointestinal system disease	29.6	MIR330 MIR215 MIR21 MIR199A1 MIR196A1 MIR193A
46	body mass index quantitative trait locus 11	29.6	TP53 MIR21 MIR199A1 MIR196A1 MIR193A MIR143
47	leukemia, chronic myeloid	29.6	TP53 MIR199A1 MIR196A1 MIR193A ERBB2 EGFR
48	gastrointestinal system cancer	29.6	MIR330 MIR215 MIR21 MIR199A1 MIR196A1 MIR193A
49	thoracic cancer	29.5	MIR330 MIR21 MIR199A1 MIR196A1 MIR193A MIR145
50	gastric cancer	29.4	TP53 TFF3 MIR215 MIR21 MIR199A1 MIR196A1

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:

Sources

Symptoms & Phenotypes for Esophagus Adenocarcinoma

Human phenotypes related to Esophagus Adenocarcinoma:

⁵⁸ ³⁰ (show all 10)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	gastroesophageal reflux ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002020
2	feeding difficulties in infancy ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0008872
3	obesity ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001513
4	clinodactyly of the 5th toe ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001864
5	barrett esophagus ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0100580
6	esophageal carcinoma ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0011459
7	nausea and vomiting ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002017
8	cough ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012735
9	chest pain ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100749
10	lymphadenopathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002716

Sources

Drugs & Therapeutics for Esophagus Adenocarcinoma

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

FOLFIRINOX

Phase 4

Pertuzumab

Approved

Phase 3

380610-27-5

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Capecitabine

Approved, Investigational

Phase 3

154361-50-9

60953

Ipilimumab

Approved

Phase 3

477202-00-9

Ramucirumab

Approved, Investigational

Phase 2, Phase 3

947687-13-0

Tucatinib

Approved, Investigational

Phase 2, Phase 3

937263-43-9

51039094

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

Hematoporphyrins

Phase 3

Pharmaceutical Solutions

Phase 3

Antibodies, Bispecific

Phase 3

Folate

Phase 3

Vitamin B9

Phase 3

Vitamins

Phase 3

Trace Elements

Phase 3

Vitamin B Complex

Phase 3

Antidotes

Phase 3

Micronutrients

Phase 3

Protective Agents

Phase 3

Trastuzumab biosimilar HLX02

Phase 3

Trioxsalen

Approved

Phase 2

3902-71-4

5585

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Erlotinib

Approved, Investigational

Phase 2

183319-69-9, 183321-74-6

176870

Everolimus

Approved

Phase 1, Phase 2

159351-69-6

70789204 6442177

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Proflavine

Approved

Phase 2

92-62-6

7099

Propranolol

Approved, Investigational

Phase 2

318-98-9, 525-66-6

62882 4946

Rucaparib

Approved, Investigational

Phase 1, Phase 2

283173-50-2

9931954

Rosiglitazone

Approved, Investigational

Phase 2

122320-73-4, 155141-29-0

77999

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Lenvatinib

Approved, Investigational

Phase 2

417716-92-8

9823820

Fulvestrant

Approved, Investigational

Phase 1, Phase 2

129453-61-8

17756771 104741

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Adenosine

Approved, Investigational

Phase 2

58-61-7

60961

Niraparib

Approved, Investigational

Phase 2

1038915-60-4

24958200

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Trifluridine

Approved, Investigational

Phase 2

70-00-8

6256

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Tremelimumab

Approved, Investigational

Phase 2

745013-59-6

Avelumab

Approved, Investigational

Phase 2

1537032-82-8

Itraconazole

Approved, Investigational

Phase 2

84625-61-6

55283

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Irinotecan

Approved, Investigational

Phase 2

97682-44-5, 100286-90-6

60838

Cisplatin

Approved

Phase 1, Phase 2

15663-27-1

2767 5702198 441203

Interventional clinical trials:

(show top 50) (show all 198)

#	Name	Status	NCT ID	Phase	Drugs
1	PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma	Recruiting	NCT02366819	Phase 4	Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
2	Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer	Unknown status	NCT02628665	Phase 3	photosensitizer(photofrin)
3	Confocal Laser Endomicroscopy for Improved Diagnosis of Barrett's Esophagus and Associated Neoplasia	Completed	NCT00487695	Phase 3
4	Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer	Recruiting	NCT03801876	Phase 3	Carboplatin;Paclitaxel;FOLFOX regimen;CAPOX regimen;Docetaxel;5FU
5	A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)	Recruiting	NCT04248452	Phase 3	Capecitabine;Fluorouracil;Leucovorin;Leucovorin Calcium;Oxaliplatin
6	A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma	Recruiting	NCT03604991	Phase 2, Phase 3	Carboplatin;Paclitaxel
7	A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma	Recruiting	NCT05568095	Phase 3	Zimberelimab;Domvanalimab;Nivolumab;Oxaliplatin;Leucovorin;Fluorouracil;Capecitabine
8	A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)	Recruiting	NCT04210115	Phase 3	placebo;cisplatin;5-FU;leucovorin;levoleucovorin;oxaliplatin
9	The Efficacy of the Addition of TRAstuzumab and Pertuzumab to Neoadjuvant Chemoradiation: a Randomized Multi-center Study in Resectable HER2 Overexpressing Adenocarcinoma of the Esophagus or Gastroesophageal Junction. The TRAP-2 Study	Recruiting	NCT05188313	Phase 3	Trastuzumab;Pertuzumab;Paclitaxel;Carboplatin
10	A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)	Recruiting	NCT05152147	Phase 3	Zanidatamab;Tislelizumab;Trastuzumab;Capecitabine;Oxaliplatin;Cisplatin;5-Fluorouracil
11	A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma	Active, not recruiting	NCT01196390	Phase 3	Carboplatin;Paclitaxel
12	Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus	Active, not recruiting	NCT02509286	Phase 3	5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
13	A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)	Active, not recruiting	NCT04499924	Phase 2, Phase 3	tucatinib;trastuzumab;ramucirumab;paclitaxel
14	A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer	Active, not recruiting	NCT02872116	Phase 3	Nivolumab;Ipilimumab;Oxaliplatin;Capecitabine;Leucovorin;Fluorouracil
15	Nutritional Supplementation for Esophageal Cancer Patients Undergoing Trimodality Therapy	Not yet recruiting	NCT04029857	Phase 3
16	A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma	Unknown status	NCT00964080	Phase 1, Phase 2	MBP-426/Leucovorin/5-FU
17	A Phase 1B/2 Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction	Completed	NCT02530437	Phase 1, Phase 2	Carboplatin;Paclitaxel;Taladegib
18	Pralatrexate in Combination With Oxaliplatin in Advanced Esophago-gastric Cancer: A Phase II Trial With Predictive Molecular Correlates	Completed	NCT01178944	Phase 2	Oxaliplatin;Pralatrexate
19	Phase II Study of Irinotecan and Panitumumab as Second-Line Therapy for Patients With Advanced Esophageal Adenocarcinoma	Completed	NCT00836277	Phase 2	Panitumumab;Irinotecan
20	A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination With AMG 386 or Placebo in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma	Completed	NCT00583674	Phase 2	AMG 386 placebo;AMG 386 10mg/kg;AMG 386 3mg/kg;Cisplatin;Capecitabine
21	Phase II Trial of Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma	Completed	NCT00354679	Phase 2	cisplatin;irinotecan hydrochloride
22	PANGEA: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma	Completed	NCT02213289	Phase 2	Trastuzumab;ABT-806;Bemarituzumab;Ramucirumab;Nivolumab;Standard cytotherapy
23	Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma	Completed	NCT01932580	Phase 2	FLOT (5-fluorouracil, oxaliplatin, docetaxel)
24	Randomized Controlled Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer	Completed	NCT02128243	Phase 2	S-1 de-escalation;Chemotherapy by Investigator's choice
25	A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors	Completed	NCT00633789	Phase 2	brivanib;Placebo
26	Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.	Completed	NCT03365791	Phase 2
27	Endoscopic Therapy of Early Cancer in Barretts Esophagus	Completed	NCT00217087	Phase 2
28	An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma	Completed	NCT01757171	Phase 2	Cabazitaxel
29	A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus	Completed	NCT00165191	Phase 2	Doxorubicin;Cisplatin;5-fluorouracil
30	A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX (Epirubicin, Oxaliplatin, Capecitabine) Regimen as First-Line Treatment of Patients With CLDN18.2-Positive Advanced Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction	Completed	NCT01630083	Phase 2	epirubicin;oxaliplatin;capecitabine;zolbetuximab
31	Phase II Trial of Cetuximab, Irinotecan, Cisplatin (CPC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer	Completed	NCT00165490	Phase 2	Cetuximab;Cisplatin;Irinotecan
32	Pre-operative Epirubicin, Capecitabine (Xeloda) and Cisplatin in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma	Completed	NCT00220103	Phase 2	epirubicin, capecitabine, cisplatin
33	A Phase II Study of Erlotinib and Modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia	Completed	NCT00591123	Phase 2	FOLFOX;5-FU;Erlotinib
34	Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.	Completed	NCT02241499	Phase 2	Oxaliplatin and fluorouracil.
35	A Phase II Study Of Triapine In Combination With Cisplatin Esophageal Carcinoma	Completed	NCT00077545	Phase 2	triapine;cisplatin
36	Phase II Study of Pralatrexate and Docetaxel in Patients With Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-based Therapy.	Completed	NCT01129206	Phase 2	pralatrexate;docetaxel
37	Phase II Study Of OSI-774 In Advanced Esophageal Cancer	Completed	NCT00045526	Phase 2	erlotinib hydrochloride
38	Pilot Trial of CRLX101 in the Treatment of Patients With Advanced Gastric, Gastroesophageal, or Esophageal Squamous or Adenocarcinoma	Completed	NCT01612546	Phase 2	cyclodextrin-based polymer-camptothecin CRLX101
39	Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients With Metastatic Gastroesophageal Adenocarcinoma	Completed	NCT01231399	Phase 1, Phase 2	fluorouracil;leucovorin calcium;oxaliplatin;everolimus
40	Phase II Trial of Pre-operative Bevacizumab and FOLFOX Chemotherapy in Locally Advanced Esophageal Cancer	Completed	NCT01212822	Phase 2	oxaliplatin;leucovorin calcium;fluorouracil
41	Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy	Completed	NCT01362127	Phase 2	Chemotherapy
42	A Phase II Study Of Preoperative Celecoxib/Paclitaxel/Carboplatin For Squamous Cell And Adenocarcinoma Of The Esophagus	Completed	NCT00066716	Phase 2	carboplatin;celecoxib;paclitaxel
43	Randomized Phase II Study of Preoperative Combined Modality Paclitaxel / Cisplatin / RT or Irinotecan / Cisplatin / RT Followed by Postoperative Chemotherapy With the Same Agents in Operable Adenocarcinoma of the Esophagus	Completed	NCT00033657	Phase 2	cisplatin;irinotecan hydrochloride;paclitaxel
44	A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach	Completed	NCT00985192	Phase 2	everolimus
45	A Phase II, Open-Label Study Evaluating Clinical Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of Lapatinib (GW572016) in Patients With Relapsed Adenocarcinoma of the Esophagus, Including Tumors of the Gastroesophageal Junction and Gastric Cardia	Completed	NCT00259987	Phase 2	Lapatinib (GW572016) oral tablets
46	Phase II Trial of Post-Operative Adjuvant Paclitaxel + Cisplatin in Patients With Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction or Cardia	Completed	NCT00003237	Phase 2	cisplatin;paclitaxel
47	Randomized Phase II Trial of Extended Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia	Completed	NCT00938470	Phase 2	capecitabine;docetaxel;fluorouracil;oxaliplatin
48	A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (With the Potential for Crossover) for Elderly and/or Poor Performance Status Patients With Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction	Completed	NCT00891878	Phase 2	capecitabine;sunitinib malate
49	A Phase II Trial of Induction Chemotherapy With Epirubicin, Oxaliplatin and Fluorouracil (EOF) Followed by Esophagogastrectomy and Post-operative Concurrent Chemoradiotherapy With Fluorouracil and Cisplatin, in Patients With Loco-regionally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Gastric Cardia	Completed	NCT00601705	Phase 2	cisplatin;epirubicin hydrochloride;fluorouracil;oxaliplatin
50	A Phase II Study of Oxaliplatin and Capecitabine in Patients With Measurable Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia	Completed	NCT00040859	Phase 2	capecitabine;oxaliplatin

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Sources

Genetic Tests for Esophagus Adenocarcinoma

Sources

Anatomical Context for Esophagus Adenocarcinoma

Organs/tissues related to Esophagus Adenocarcinoma:

MalaCards : Lymph Node, Liver, Bone Marrow, Skeletal Muscle, Lung, Breast, Endothelial

Sources

Publications for Esophagus Adenocarcinoma

Articles related to Esophagus Adenocarcinoma:

(show top 50) (show all 6524)

#	Title	Authors	PMID	Year
1	MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. ⁶² ⁴⁶	Wijnhoven BP...South Australian Oesophageal Research Group	20301167	2010
2	Cervical esophageal adenocarcinoma of intestinal type in ectopic gastric mucosa. ⁶²	Ikeda R...Maeda S	35898822	2023
3	Incidence and Impact of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent. ⁶²	Reynolds JV...Donohoe CL	36264338	2023
4	Patient Knowledge, Risk Perception, and Barriers to Barrett's Esophagus Screening. ⁶²	Kolb JM...Wani S	36219171	2022
5	AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review. ⁶²	Muthusamy VR...CGIT Barrett's Esophagus Consensus Conference Participants	35788412	2022
6	Diverse contributions of the visceral fat area to the etiology of two distinct subtypes of esophago-gastric junctional adenocarcinoma. ⁶²	Watanabe K...Iijima K	35737566	2022
7	Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go? ⁶²	Rogers JE...Ajani JA	36286544	2022
8	Next Generation Sequencing for Potential Regulated Genes and Micro-RNAs of Early Growth Response-1 in the Esophageal Squamous Cell Carcinoma. ⁶²	Tseng YC...Tseng CJ	36207572	2022
9	Detection of Barrett's neoplasia with a near-infrared fluorescent heterodimeric peptide. ⁶²	Chen J...Wang TD	35299273	2022
10	Long-term fear of cancer recurrence in patients treated endoscopically for early Barrett's neoplasia. ⁶²	Rosmolen WD...Nieuwkerk PT	36461786	2022
11	Integrin beta1 (ITGB1) as a prognostic marker in esophageal adenocarcinoma. ⁶²	Damanakis AI...Gebauer F	36456612	2022
12	Change in Density Not Size of Esophageal Adenocarcinoma During Neoadjuvant Chemotherapy Is Associated with Improved Survival Outcomes. ⁶²	Tankel J...Cools-Lartigue J	36214951	2022
13	Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. ⁶²	Cabeza-Segura M...Fleitas T	36253523	2022
14	Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy. ⁶²	Holmberg D...Lagergren J	36258093	2022
15	Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy. ⁶²	Davern M...Lysaght J	36445478	2022
16	Generation and multiomic profiling of a TP53/CDKN2A double-knockout gastroesophageal junction organoid model. ⁶²	Zhao H...Meltzer SJ	36449602	2022
17	Controversies in upper gastrointestinal oncology: neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in oesophageal adenocarcinoma. ⁶²	Petrillo A...van Laarhoven HWM	36356415	2022
18	RAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid Tumors. ⁶²	Liao C...Shammas MA	36428789	2022
19	The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett's Neoplasia. ⁶²	Venkitachalam S...Guda K	35870513	2022
20	Antitumor effects of lactate transport inhibition on esophageal adenocarcinoma cells. ⁶²	Grasa L...Piazuelo E	36342616	2022
21	An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma. ⁶²	Cools-Lartigue J...Ferri L	35861351	2022
22	Clinical Understaging, Treatment Response, and Survival Among Esophageal Adenocarcinoma Patients. ⁶²	da Costa WL...Massarweh NN	35797753	2022
23	Comment on: The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-Negative Esophageal Adenocarcinoma. ⁶²	Wang S...Qiao G	34793349	2022
24	[Oesogastric cancer - new therapeutic targets]. ⁶²	Palmieri LJ...Pernot S	36371284	2022
25	Safety and efficacy of liquid nitrogen spray cryotherapy in Barrett's neoplasia - a comprehensive review and meta-analysis. ⁶²	Chandan S...Adler DG	36397870	2022
26	Global variations in diagnostic guidelines for Barrett's esophagus. ⁶²	Kusano C...Gotoda T	35475586	2022
27	Barrett's Esophagus and Esophageal Adenocarcinoma: A Histopathological Perspective. ⁶²	Zyla RE...Kalimuthu SN	36266029	2022
28	Development and External Validation of a Model to Predict Complex Treatment After Radiofrequency Ablation for Barrett's Esophagus With Early Neoplasia. ⁶²	van Munster SN...Pouw RE	35292379	2022
29	A risk variant for Barrett's esophagus and esophageal adenocarcinoma at chr8p23.1 affects enhancer activity and implicates multiple gene targets. ⁶²	Ali MW...Buas MF	35766871	2022
30	CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma: A Propensity-Matched Comparison. ⁶²	Donlon NE...Reynolds JV	35876385	2022
31	Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma. ⁶²	Matani H...Goel A	36376989	2022
32	Proton Beam Therapy With Space-Making Surgery (Omental Plombage) for Oligorecurrent Liver Metastasis of Esophageal Adenocarcinoma. ⁶²	Ishikawa Y...Murakami M	36415474	2022
33	Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis. ⁶²	Ge F...Liu J	36322089	2022
34	Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer. ⁶²	Dings MPG...Bijlsma MF	36334593	2022
35	Ongoing Controversies in Esophageal Cancer II: Gastrectomy versus Esophagectomy for Siewert Type II Esophageal Adenocarcinoma. ⁶²	Devaud N...Carroll P	36266040	2022
36	Immune Checkpoint Blockade and Targeted Therapies in Esophageal Cancer. ⁶²	Yang J...Janjigian YY	36266034	2022
37	High spicy food intake may increase the risk of esophageal cancer: A meta-analysis and systematic review. ⁶²	Xie P...Sun C	36215887	2022
38	Esophageal Cancer Genetics and Clinical Translation. ⁶²	Jajosky A...Fels Elliott DR	36266030	2022
39	Global and national trends in the age-specific sex ratio of esophageal cancer and gastric cancer by subtype. ⁶²	Wang S...He J	35678331	2022
40	Laparoscopic total fundoplication is superior to medical treatment for reducing the cancer risk in Barrett's esophagus: a long-term analysis. ⁶²	Szachnowicz S...Cecconello I	35641160	2022
41	Effect of hiatus hernia on reflux patterns and mucosal integrity in patients with non-erosive reflux disease. ⁶²	Sawada A...Sifrim D	35593218	2022
42	Low Prevalence of Endoscopic Screening for Barrett's Esophagus in a Screening-Eligible Primary Care Population. ⁶²	Eluri S...Shaheen NJ	35971219	2022
43	A blood-based circulating microbial metagenomic panel for early diagnosis and prognosis of oesophageal adenocarcinoma. ⁶²	Zaidi AH...Goel A	36097175	2022
44	Gastroesophageal Reflux Disease Is Not a Great Screening Criterion: Time to Move on to Other Strategies for Controlling the Burden of Esophageal Adenocarcinoma. ⁶²	Rubenstein JH	36327434	2022
45	Progressive dysbiosis of human orodigestive microbiota along the sequence of gastroesophageal reflux, Barrett's esophagus and esophageal adenocarcinoma. ⁶²	Hao Y...Pei Z	35751398	2022
46	Sleeve-Dor Fundoplication - An Innovative Surgical Technique to Avoid the Epidemic Long Term de Novo Gastroesophageal Reflux and Barrett´s Esophagus After Sleeve Gastrectomy for Obesity. ⁶²	Li R...Zorron R	36413570	2022
47	Barrett Esophagus: Rapid Evidence Review. ⁶²	Bryce C...Gazda R	36260894	2022
48	Augmented CPT1A Expression Is Associated with Proliferation and Colony Formation during Barrett's Tumorigenesis. ⁶²	Bernard JN...Andl CD	36233047	2022
49	Columnar Metaplasia of the Esophagus Presenting as Iron Deficiency Anemia in Children with Neurologic Impairment or Congenital Esophageal Atresia. ⁶²	Van Arsdall MR...Rhoads JM	36225096	2022
50	International trends in esophageal cancer incidence rates by histological subtype (1990-2012) and prediction of the rates to 2030. ⁶²	Lin Y...Wu J	35689719	2022

Sources

Genes for Esophagus Adenocarcinoma

Genes related to Esophagus Adenocarcinoma (0 elite genes):

(show all 30)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	HNF1A-AS1	HNF1A Antisense RNA 1	RNA Gene	155.99	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	24000294
2	AFAP1-AS1	AFAP1 Antisense RNA 1	RNA Gene	153.48	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	23333711
3	MIR21	MicroRNA 21	RNA Gene	54.28	Unspecified ⁴⁶ DISEASES inferred ¹⁴	20301167
4	MIR215	MicroRNA 215	RNA Gene	54.28	Unspecified ⁴⁶ DISEASES inferred ¹⁴	20301167
5	MIR143	MicroRNA 143	RNA Gene	54.12	Unspecified ⁴⁶ DISEASES inferred ¹⁴	20301167
6	MIR145	MicroRNA 145	RNA Gene	53.82	Unspecified ⁴⁶ DISEASES inferred ¹⁴	20301167
7	MIR196A1	MicroRNA 196a-1	RNA Gene	9.2	DISEASES inferred ¹⁴ ¹⁴
8	MIR330	MicroRNA 330	RNA Gene	8.28	DISEASES inferred ¹⁴ ¹⁴
9	MIR505	MicroRNA 505	RNA Gene	6.87	DISEASES inferred ¹⁴ ¹⁴
10	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	6.56	DISEASES inferred ¹⁴
11	ATP4A	ATPase H+/K+ Transporting Subunit Alpha	Protein Coding	6.56	DISEASES inferred ¹⁴
12	MIR345	MicroRNA 345	RNA Gene	6.37	DISEASES inferred ¹⁴ ¹⁴
13	TP53	Tumor Protein P53	Protein Coding	6.34	DISEASES inferred ¹⁴
14	MIR199A1	MicroRNA 199a-1	RNA Gene	6.27	DISEASES inferred ¹⁴ ¹⁴
15	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	6.17	DISEASES inferred ¹⁴
16	TFF3	Trefoil Factor 3	Protein Coding	5.74	DISEASES inferred ¹⁴
17	LEPROTL1	Leptin Receptor Overlapping Transcript Like 1	Protein Coding	5.71	DISEASES inferred ¹⁴
18	MIR193A	MicroRNA 193a	RNA Gene	5.66	DISEASES inferred ¹⁴ ¹⁴
19	CDX2	Caudal Type Homeobox 2	Protein Coding	5.65	DISEASES inferred ¹⁴
20	EGFR	Epidermal Growth Factor Receptor	Protein Coding	5.64	DISEASES inferred ¹⁴
21	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	5.62	DISEASES inferred ¹⁴
22	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	5.45	DISEASES inferred ¹⁴
23	TAGLN2	Transgelin 2	Protein Coding	5.37	DISEASES inferred ¹⁴
24	BEST2	Bestrophin 2	Protein Coding	5.35	DISEASES inferred ¹⁴
25	CCND1	Cyclin D1	Protein Coding	5.34	DISEASES inferred ¹⁴
26	GPX7	Glutathione Peroxidase 7	Protein Coding	5.29	DISEASES inferred ¹⁴
27	COX7A2	Cytochrome C Oxidase Subunit 7A2	Protein Coding	5.25	DISEASES inferred ¹⁴
28	CTNNB1	Catenin Beta 1	Protein Coding	5.22	DISEASES inferred ¹⁴
29	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	5.21	DISEASES inferred ¹⁴
30	CDH1	Cadherin 1	Protein Coding	5.21	DISEASES inferred ¹⁴

Sources

Variations for Esophagus Adenocarcinoma

Cosmic variations for Esophagus Adenocarcinoma:

⁸ (show top 50) (show all 11464)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM94780361	ZNF521	stomach,NS,carcinoma,adenocarcinoma	c.1159G>A	p.A387T	18:25226759-25226759	10
2	COSM131486960	ZNF521	stomach,NS,carcinoma,adenocarcinoma	c.1159G>A	p.A387T	18:25226759-25226759	10
3	COSM140706619	ZNF521	stomach,NS,carcinoma,adenocarcinoma	c.499G>A	p.A167T	18:25226759-25226759	10
4	COSM94777296	ZNF521	stomach,NS,carcinoma,adenocarcinoma	c.2285G>A	p.R762H	18:25225633-25225633	10
5	COSM131495211	ZNF521	stomach,NS,carcinoma,adenocarcinoma	c.443G>A	p.C148Y	18:25227475-25227475	10
6	COSM140704933	ZNF521	stomach,NS,carcinoma,adenocarcinoma	c.1625G>A	p.R542H	18:25225633-25225633	10
7	COSM94795709	ZNF521	stomach,NS,carcinoma,adenocarcinoma	c.3434T>G	p.V1145G	18:25224484-25224484	10
8	COSM94788727	ZNF521	stomach,NS,carcinoma,adenocarcinoma	c.443G>A	p.C148Y	18:25227475-25227475	10
9	COSM140712668	ZNF521	stomach,NS,carcinoma,adenocarcinoma	c.-218G>A	p.?	18:25227475-25227475	10
10	COSM131483683	ZNF521	stomach,NS,carcinoma,adenocarcinoma	c.2285G>A	p.R762H	18:25225633-25225633	10
11	COSM131502188	ZNF521	stomach,NS,carcinoma,adenocarcinoma	c.3434T>G	p.V1145G	18:25224484-25224484	10
12	COSM140717636	ZNF521	stomach,NS,carcinoma,adenocarcinoma	c.2774T>G	p.V925G	18:25224484-25224484	10
13	COSM89892679	ZNF384	stomach,NS,carcinoma,adenocarcinoma	c.1136G>A	p.R379Q	12:6669044-6669044	10
14	COSM99686061	ZNF384	stomach,NS,carcinoma,adenocarcinoma	c.1319G>A	p.R440Q	12:6669044-6669044	10
15	COSM96892872	ZNF384	stomach,NS,carcinoma,adenocarcinoma	c.1319G>A	p.R440Q	12:6669044-6669044	10
16	COSM92495186	ZNF384	stomach,NS,carcinoma,adenocarcinoma	c.971G>A	p.R324Q	12:6669044-6669044	10
17	COSM90523509	ZNF341	stomach,NS,carcinoma,adenocarcinoma	c.2512G>A	p.A838T	20:33791485-33791485	10
18	COSM98293254	ZNF341	stomach,NS,carcinoma,adenocarcinoma	c.2533G>A	p.A845T	20:33791485-33791485	10
19	COSM84509305	ZNF276	stomach,NS,carcinoma,adenocarcinoma	c.*677T>G	p.?	16:89738923-89738923	10
20	COSM102042239	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.5456G>T	p.R1819L	16:72794484-72794484	10
21	COSM149288723	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.1081G>A	p.G361R	16:72959065-72959065	10
22	COSM149261321	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.1858C>T	p.H620Y	16:72958288-72958288	10
23	COSM102020152	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.-23-7323C>T	p.?	16:72958288-72958288	10
24	COSM87271088	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.1858C>T	p.H620Y	16:72958288-72958288	10
25	COSM87290698	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.795C>A	p.D265E	16:72959351-72959351	10
26	COSM87291716	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.4553G>T	p.G1518V	16:72798129-72798129	10
27	COSM149332052	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.5929G>C	p.G1977R	16:72796753-72796753	10
28	COSM87280547	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.1081G>A	p.G361R	16:72959065-72959065	10
29	COSM102040971	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.-23-8386C>A	p.?	16:72959351-72959351	10
30	COSM87291652	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.8198G>T	p.R2733L	16:72794484-72794484	10
31	COSM87296752	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.5929G>C	p.G1977R	16:72796753-72796753	10
32	COSM149318848	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.4553G>T	p.G1518V	16:72798129-72798129	10
33	COSM149318790	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.8198G>T	p.R2733L	16:72794484-72794484	10
34	COSM102042308	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.1811G>T	p.G604V	16:72798129-72798129	10
35	COSM149315912	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.795C>A	p.D265E	16:72959351-72959351	10
36	COSM102030210	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.-23-8100G>A	p.?	16:72959065-72959065	10
37	COSM102048038	ZFHX3	stomach,NS,carcinoma,adenocarcinoma	c.3187G>C	p.G1063R	16:72796753-72796753	10
38	COSM89893344	YES1	stomach,NS,carcinoma,adenocarcinoma	c.350G>A	p.R117K	18:751726-751726	10
39	COSM136835352	YES1	stomach,NS,carcinoma,adenocarcinoma	c.365G>A	p.R122K	18:751726-751726	10
40	COSM152021882	YES1	stomach,NS,carcinoma,adenocarcinoma	c.350G>A	p.R117K	18:751726-751726	10
41	COSM143039512	YAP1	stomach,NS,carcinoma,adenocarcinoma	c.356C>G	p.T119S	11:102114178-102114178	10
42	COSM145026456	YAP1	stomach,NS,carcinoma,adenocarcinoma	c.356C>G	p.T119S	11:102114178-102114178	10
43	COSM85235472	YAP1	stomach,NS,carcinoma,adenocarcinoma	c.356C>G	p.T119S	11:102114178-102114178	10
44	COSM128450026	YAP1	stomach,NS,carcinoma,adenocarcinoma	c.356C>G	p.T119S	11:102114178-102114178	10
45	COSM126971185	YAP1	stomach,NS,carcinoma,adenocarcinoma	c.-179C>G	p.?	11:102114178-102114178	10
46	COSM133271379	YAP1	stomach,NS,carcinoma,adenocarcinoma	c.356C>G	p.T119S	11:102114178-102114178	10
47	COSM127996054	YAP1	stomach,NS,carcinoma,adenocarcinoma	c.356C>G	p.T119S	11:102114178-102114178	10
48	COSM90945716	YAP1	stomach,NS,carcinoma,adenocarcinoma	c.356C>G	p.T119S	11:102114178-102114178	10
49	COSM97252932	XRCC2	stomach,NS,carcinoma,adenocarcinoma	c.140A>G	p.H47R	7:152649345-152649345	10
50	COSM101975785	XPO1	stomach,NS,carcinoma,adenocarcinoma	c.479G>A	p.S160N	2:61499824-61499824	10

Copy number variations for Esophagus Adenocarcinoma from CNVD:

⁶ (show top 50) (show all 85)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	18052	1	143700001	144900000	Amplification	BCL9	Esophageal adenocarcinoma
2	19685	1	151000001	155000000	Amplification	SKI	Esophageal adenocarcinoma
3	29301	1	2300000	5400000	Copy number		Esophageal adenocarcinoma
4	37058	1	84900000	107200000	Loss	F3	Esophageal adenocarcinoma
5	47055	10	89500000	92900000	Copy number		Esophageal adenocarcinoma
6	49101	11	102900000	110400000	Copy number		Esophageal adenocarcinoma
7	53078	11	2400000	5900000	Copy number	CDKN1C	Esophageal adenocarcinoma
8	57455	11	63400000	77100000	Gain	CCND1	Esophageal adenocarcinoma
9	57457	11	63400000	77100000	Gain	CTTN	Esophageal adenocarcinoma
10	57458	11	63400000	77100000	Gain	FGF3	Esophageal adenocarcinoma
11	64928	12	133416937	133464204	Copy number	CHFR	Esophageal adenocarcinoma
12	76216	13	28900000	32200000	Gain	BRCA2	Esophageal adenocarcinoma
13	80630	13	95000000	115169878	Gain	ABCC4	Esophageal adenocarcinoma
14	80631	13	95000000	115169878	Gain	ING1	Esophageal adenocarcinoma
15	92864	15	44800000	63700000	Loss	B2M	Esophageal adenocarcinoma
16	95624	15	78300000	102531392	Loss	IGF1R	Esophageal adenocarcinoma
17	105374	16	7900000	10500000	Copy number		Esophageal adenocarcinoma
18	106764	17	1	20774742	Copy number	MYBBP1A	Esophageal adenocarcinoma
19	106765	17	1	20774742	Copy number	TP53	Esophageal adenocarcinoma
20	109778	17	2912016	3092354	Gain and loss		Esophageal adenocarcinoma
21	110805	17	34303536	34308523	Gain	CCL3	Esophageal adenocarcinoma
22	112093	17	37856253	37884915	Gain	ERBB2	Esophageal adenocarcinoma
23	112536	17	400000	1400000	Copy number		Esophageal adenocarcinoma
24	118020	17	7512444	7519279	Deletion	TP53	Esophageal adenocarcinoma
25	119909	18	18180001	18280000	Amplification	CTAGE1	Esophageal adenocarcinoma
26	121327	18	42300001	49000000	Copy number		Esophageal adenocarcinoma
27	121739	18	46700000	46950000	Copy number	ELAC1	Esophageal adenocarcinoma
28	121740	18	46700000	46950000	Copy number	ME2	Esophageal adenocarcinoma
29	121741	18	46700000	46950000	Copy number	SMAD4	Esophageal adenocarcinoma
30	121934	18	49866541	51062273	Loss	DCC	Esophageal adenocarcinoma
31	122288	18	54600001	58000000	Copy number	MC4R	Esophageal adenocarcinoma
32	122514	18	57567191	57571538	Loss	PMAIP1	Esophageal adenocarcinoma
33	122776	18	60790578	60986613	Loss	BCL2	Esophageal adenocarcinoma
34	123455	18	72900000	73900000	Copy number	GALR1	Esophageal adenocarcinoma
35	123456	18	72900000	73900000	Copy number	MBP	Esophageal adenocarcinoma
36	134361	2	10000000	85000000	Copy number	MSH2	Esophageal adenocarcinoma
37	134362	2	10000000	85000000	Copy number	MYCN	Esophageal adenocarcinoma
38	142764	2	230000001	238400000	Copy number		Esophageal adenocarcinoma
39	150784	20	14500000	15536000	Copy number		Esophageal adenocarcinoma
40	153497	20	37600000	49800000	Gain	NCOA3	Esophageal adenocarcinoma
41	153498	20	37600000	49800000	Gain	PTPN1	Esophageal adenocarcinoma
42	154843	20	49100001	52300000	Amplification	ZNF217	Esophageal adenocarcinoma
43	157694	21	21500001	25000000	Copy number		Esophageal adenocarcinoma
44	157695	21	21500001	25000000	Copy number	NCAM2	Esophageal adenocarcinoma
45	162985	22	23500000	25900000	Loss	MIF	Esophageal adenocarcinoma
46	190407	4	88000000	98800000	Loss	ABCG2	Esophageal adenocarcinoma
47	190850	4	91513360	92060333	Copy number		Esophageal adenocarcinoma
48	193495	5	130600000	144500000	Loss	IL13	Esophageal adenocarcinoma
49	200116	5	50107903	180611420	Gain and loss	APC	Esophageal adenocarcinoma
50	200117	5	50107903	180611420	Gain and loss	CCNB1	Esophageal adenocarcinoma

Sources

Expression for Esophagus Adenocarcinoma

Search GEO for disease gene expression data for Esophagus Adenocarcinoma.

Sources

Pathways for Esophagus Adenocarcinoma

Pathways related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.4	MIR199A1 MIR145 MIR143
2	Head and neck squamous cell carcinoma ⁷⁴	11.3	TP53 ERBB2 EGFR
3	miRNAs involvement in the immune response in sepsis ⁷⁴	11.12	MIR21 MIR199A1 MIR145
4	miRNAs involved in DNA damage response ⁷⁴	10.85	TP53 MIR330 MIR21 MIR145 MIR143
5	Bladder cancer ⁷⁴	10.73	TP53 ERBB2 EGFR

Sources

GO Terms for Esophagus Adenocarcinoma

Cellular components related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.58	MIR505 MIR345 MIR330 MIR215 MIR21 MIR199A1

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 12)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of protein kinase B signaling	GO:0051897	9.88	MIR21 MIR199A1 MIR143 EGFR
2	regulation of ERK1 and ERK2 cascade	GO:0070372	9.83	MIR145 ERBB2 EGFR
3	negative regulation of cell migration involved in sprouting angiogenesis	GO:0090051	9.63	MIR199A1 MIR196A1 MIR193A
4	miRNA-mediated gene silencing	GO:0035195	9.6	MIR505 MIR345 MIR330 MIR215 MIR21 MIR199A1
5	negative regulation of cardiac muscle cell apoptotic process	GO:0010667	9.58	MIR21 MIR199A1 MIR145
6	positive regulation of miRNA maturation	GO:1903800	9.51	TP53 EGFR
7	aorta smooth muscle tissue morphogenesis	GO:0060414	9.49	MIR145 MIR143
8	regulation of phenotypic switching	GO:1900239	9.37	MIR145 MIR143
9	negative regulation of angiogenesis	GO:0016525	9.35	MIR505 MIR21 MIR193A MIR145 MIR143
10	negative regulation of interleukin-21 production	GO:0032705	9.32	MIR215 MIR21
11	positive regulation of cellular response to hypoxia	GO:1900039	9.26	MIR21 MIR145
12	establishment or maintenance of cell type involved in phenotypic switching	GO:0044663	9.16	MIR143 MIR145

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	P-type sodium:potassium-exchanging transporter activity	GO:0005391	9.62	ATP4A ATP12A
2	mRNA 3'-UTR binding	GO:0003730	9.5	TP53 MIR21 MIR199A1 MIR193A MIR145 MIR143
3	P-type potassium:proton transporter activity	GO:0008900	9.46	ATP4A ATP12A
4	mRNA base-pairing translational repressor activity	GO:1903231	9.32	MIR505 MIR345 MIR330 MIR215 MIR21 MIR199A1
5	P-type potassium transmembrane transporter activity	GO:0008556	9.26	ATP4A ATP12A